TrialThe British journal of dermatology2022

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.

R Oliver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.